Follow Us On

Facebook  X  Linkedin  YouTube
 
 

Time to Submit Comment

Letters to CMS and Congress!


CMS has issued two proposed rules that will set 2027 Medicare payment for interventional pain management: the CY 2027 Physician Fee Schedule and the CY 2027 OPPS/ASC Payment System. ASIPP is commenting on both. We ask that every State Society also file its own separate comment letter. Letters from societies across the country show CMS the nationwide impact on physicians, independent practices, ASCs, and Medicare patients.


Here is the link to our sample letter:

Comment Deadline is Monday, September 14, 2026

INSTRUCTIONS FOR OPENING LETTER

When you click on the sample letter link, the letter will automatically download to your Downloads folder.


Please use the letter as a starting point, not as a form.

Identical letters carry little weight with CMS. We ask you to rewrite using your own letterhead, change the wording and order, add state-specific examples, and keep ASIPP’s key issues and requests.

 

Please also write to Congress. Send letters to both of your U.S. Senators and to one member of your U.S. House delegation, asking for an annual inflation update to Medicare physician payment and relief from budget neutrality.


Click here for Senator contact information.

Click here for Representative contact information.


The Physician Fee Schedule comment deadline is less than one week away. Please act now.


Thank you for your continued support and advocacy on behalf of ASIPP and Medicare beneficiaries.

Discover how the Intracept™ Procedure is delivering a new standard of care for vertebrogenic pain

Join our webinar on Wednesday, September 9, at 7 pm ET, hosted in collaboration with the American Society of Interventional Pain Physicians (ASIPP), to discover how to diagnose this distinct condition and why the Intracept Procedure is a proven, purpose-built treatment option.

Her Breast MRI Was Approved, But That Didn’t Mean Her Insurance Would Pay 

A woman in Washington state discovered that unlike mammograms, breast MRIs aren’t universally covered as zero-cost preventive care.


Last year, Stephanie Halver’s primary care doctor consulted a risk assessment tool to calculate her chances of one day developing breast cancer. Halver, now 43, remembered the likelihood “popped up really high.”


That’s partly because Halver’s mother and aunt have had breast cancer. Her age and dense breast tissue also put her at higher risk.


Halver, who lives in Vancouver, Washington, said her doctor recommended she get an annual breast MRI, six months after her yearly mammogram. The scan would serve as an additional safeguard, since breast MRIs can detect abnormalities that mammograms miss.


Case in point, actress Olivia Munn had a breast MRI in 2023 that detected an aggressive form of cancer in both breasts, even though a recent mammogram had been clear, she told People magazine. Like Halver, Munn said her doctor recommended the MRI after a risk assessment score showed she faced a greater-than-normal chance of developing breast cancer.


Click here to read the full article.

 

ASIPP has submitted a proposal to the Centers for Medicare & Medicaid Services (CMS) proposing the creation of an Independent Physician Payment Modifier under Medicare.


The proposal is intended to help preserve independent physician practices by establishing a modifier that would identify qualifying independent physicians and provide a 10% payment adjustment for eligible physician services, while maintaining budget neutrality and protecting existing facility payments.


Click here to view ASIPP’s Letter to Joseph Albanese, CMS/CM


Click here to view ASIPP’s Proposed Modifier for Independent Physician Services

 

CMS has released the CY 2027 Medicare Physician Fee Schedule Proposed Rule (CMS-1848-P). The overall picture is unfavorable: CMS estimates a combined -2% impact on interventional pain management, with additional proposals affecting E/M billing, MIPS, and imaging/laboratory payment. Two documents are attached — the proposed rule and ASIPP’s code-by-code payment comparison for 2027 vs. 2026. Key points below.

 

Conversion Factor: Proposed Cut

With the one-year 2.5% statutory increase for 2026 expiring, CMS proposes:

  • Qualifying APM participants: $33.17, down from $33.57 (-1.19%)
  • All other clinicians (non-QP): $32.84, down from $33.40 (-1.68%)

These figures reflect a +0.53% budget-neutrality adjustment and statutory updates of +0.75% (QP) and +0.25% (non-QP). They do not include the 2% sequester or potential 4% PAYGO cuts.

 

IPM Codes: Widespread Reductions vs. 2026

Most interventional pain codes are cut 1–6% in the office setting and 1-4% in Facility:

Office Setting

Facility Setting

Epidurals

(62321 & 62323)

-3.0% to -3.3%

-2.7% to -3.0%

Transforaminal

(64479 to 64484)

-3.7% to -4.9%

-1.2% to -3.8%

Facet joint

(64490-64495)

-1.3% to -3.5%

-1.2% to -3.6%

Radiofrequency Ablation (64633-36)

-4.9% to -5.2%

-1.2% to -3.3%

SCS Lead Placement (63650)

-5.9%

-3.0%

EM Services

(99203-205, 213-215)

1.4% to -3.8%

-1.2% to -2.5%

  • Trigeminal nerve injection (64400): -19.9%; greater occipital nerve (64405): -16.6%
  • Percutaneous SI joint fusion (27279, facility): -14.9%
  • Kyphoplasty (22513–22515): -6.0% to -6.1%
  • Spinal cord stimulator trial (63650): -5.9%; percutaneous
  • PNS (64555): -6.3%


A handful of codes see small increases (e.g., blood patch 62273, several peripheral nerve blocks). The attached table shows every IPM code.


E/M Services: Major Change to Modifier -25

CMS proposes that when a separately identifiable office E/M visit is billed with modifier -25 on the same day as a 0-, 10-, or 90-day global procedure, only the highest-paid service is paid at 100% — all others, including the E/M visit, are cut 50%. This directly targets the common office-based scenario of a same-day evaluation and injection. CMS also proposes replacing add-on code G2211 with modifier MOD1, valued at 16% of the base E/M code (32% for ACO participants via MOD2). E/M payment rates themselves decline modestly (see attached table).


MIPS / Quality Payment Program

  • Traditional MIPS would sunset with the CY 2029 performance period (2031 payment year), making MIPS Value Pathways (MVPs) the sole reporting option; three new MVPs are proposed.
  • The quality measure inventory would be set at 180 measures (20 removals, 10 additions), with a new MIPS core measure reporting requirement replacing the outcome/high-priority measure requirement (small practices exempt).
  • The performance threshold remains 75 points. Separately, the rule proposes refinements to the Ambulatory Specialty Model (ASM), the mandatory model whose low back pain cohort includes interventional pain physicians.


RFI: Duplicate Laboratory Testing, Imaging, and Interoperability

CMS is seeking input on mechanisms to address duplicate laboratory and imaging tests, including MAC edits resulting in non-payment or reduced payment, recoupment of payments, frequency limitations, and revised billing instructions, along with improved result sharing and interoperability. These policies could significantly affect pain practices that rely on imaging and drug testing. ASIPP will submit detailed comments — please send us your input.


Act Now

Comments are due September 14, 2026 (file code CMS-1848-P). Please review the attached documents and send your feedback to asipp@asipp.org so we can represent you forcefully. ASIPP will fight these cuts, as we always have — but your voice makes the difference.


View the CY 2027 PFS Proposed Rule Fact Sheet


View the ASIPP 2027 vs. 2026 Proposed Payment Rate Comparison for IPM Codes

 

SAVE THE DATE - APRIL 15-17, 2027

Save the date for the American Society of Interventional Pain Physicians' 29th Annual Meeting, April 15 - 17, 2027, in Orlando, Florida.


This flagship educational event will bring together physicians, researchers, and healthcare professionals from across the country for three days of cutting-edge education, collaboration, and professional networking.


Attendees can look forward to our most comprehensive Annual Meeting yet, featuring new educational topics, expanded faculty participation, and innovative program enhancements designed to keep you at the forefront of interventional pain management.


Mark your calendar now and plan to join us in Orlando as we continue advancing excellence in interventional pain management. Additional program details and faculty announcements will be released soon.


Register by October 1, 2026, to receive a 10% Early Bird Discount.

ASIPP is expanding opportunities for Residents and Fellows at the 2027 Annual Meeting, with more ways to present, participate, connect, and represent fellowship programs.


Present Your Research  |  Connect with Program Directors

Represent Your Program  |  Programming for Residents & Fellows


Ready to Take Your Place?

Residents and Fellows can submit an abstract to share their research at ASIPP 2027 or apply for a scholarship to help make attending the Annual Meeting possible.

Unruptured Brain Aneurysms Found in 1 in 15 Healthy Adults, Study Shows

Prevalence is rising, and better imaging isn't the whole reason

 

Key Takeaways


• The prevalence of unruptured brain aneurysm rose from 2.9% to 6.6% over two decades, a systematic review and meta-analysis showed.


• The higher prevalence appeared partly independent of the aging population and improved imaging, suggesting that unknown risk factors may play a role.


• Researchers supported targeted screening for high-risk groups, not broad screening of healthy adults.

Unruptured brain aneurysms were identified more frequently in recent years, a systematic review and meta-analysis showed.


In studies of healthy people who had MR or CT angiography, the prevalence of an unruptured intracranial aneurysm rose from 2.9% to 6.6% over two decades, reported Nima Etminan, MD, of the University of Heidelberg in Mannheim, Germany, and co-authors.


After adjusting for age and sex, the prevalence ratio was 1.8 (95% CI 1.1-2.8) for 2016-2022 compared with 2002-2015.


Click here to read the full article.

ASIPP is proud to launch our Resident and Fellow Mentorship Program. This initiative is designed to connect trainees with experienced pain physicians to foster professional growth, provide guidance, and strengthen the future of our specialty.


Each mentor would be paired with one to two trainees, but can take more if interested. Trainees will be responsible for initiating introductions and arranging at least one to two video calls per year. These sessions will provide opportunities for mentees to seek advice on clinical decision-making, career planning, research opportunities, and professional development.


We believe that your experience, expertise, and insight can have a lasting impact on the next generation of pain physicians. By volunteering as a mentor, you will play a critical role in shaping the future of our field and ensuring that ASIPP continues to cultivate excellence in interventional pain medicine.


If you are interested in serving as a mentor, please confirm your participation by filling out the appropriate form below.

Why Dolly Parton's an Excellent Role Model for Doctors 

She built a career not only on talent, but on humility, authenticity, resilience, and generosity


Dolly Parton died last month at age 80. Her death has prompted extensive coverage of her humanitarian and healthcare legacy. My big takeaway from learning more about her: Parton is a wonderful role model for physicians because many of the qualities that made her successful are exactly the qualities medicine needs.

 

She Was Humble While Becoming Exceptional

Parton achieved extraordinary success without abandoning her down-to-earth personality. Although patients and society may place physicians on a pedestal because of their knowledge and stature, it is important to emulate Parton and avoid becoming unapproachable. Although no one will be asking for our autographs, our egos can swell, but we must remain kind, compassionate, and empathetic.

 

She Never Forgot Where She Came From

Parton's Appalachian roots remain central to her identity. She was born in the woods in a two-room cabin with no running water and no electricity, with her 11 siblings. Parton never forgot where she came from and credited the hardscrabble life of her early years with motivating her to be outstanding in everything she did.


Doctors should never forget their years of training and the challenges of deferred gratification. Remember that medicine is ultimately about patients -- not credentials, technology, or status.


Click here to read the full article.

ASIPP is pleased to announce the launch of the Regenerative and Longevity Medicine Section!


This section reflects the growing importance of regenerative and longevity medicine—fields dedicated to restoring health, enhancing vitality, and extending the healthy years of life. From stem cell therapies and tissue engineering to gene therapy and orthobiologics, these disciplines are transforming the way we approach pain management and age-related decline.


Section membership offers:

  • Access to ASIPP’s physician database and future data registry
  • Opportunities for certification and continuing education
  • Section-exclusive resources and updates


No additional cost for ASIPP members!

As GLP-1 Use Expands Into Dermatology,

So Do the Medicolegal Implications

Off-label indications, use of compounded

products could increase liability exposure

 

Key Takeaways


• Medical liability cases related to GLP-1 receptor agonist use in dermatology have been uncommon to date.

 

• Increased interest in GLP-1 agonists to treat psoriasis and inflammatory skin conditions has the potential to increase liability exposure for dermatologists.

 

• Dermatologists who prescribe GLP-1 drugs should be familiar with their indications and protocols and ensure appropriate patient counseling and informed consent.

Medical liability cases involving GLP-1 receptor agonist use in dermatology have occurred infrequently to date but warrant careful attention as the use increases, a medicolegal review suggests.


A review of the LexisNexis legal research database identified 21 GLP-1-related cases through February 2026, only six since 2021. The pattern of litigation shifted over time, as early cases most often involved failure-to-warn claims related to pancreatitis and pancreatic cancer. More recent cases involving semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) involved weight loss and centered on alleged negligence in prescribing and informing patients about gastrointestinal symptoms, reported Shari R. Lipner, MD, PhD, of Weill Cornell Medicine in New York City, and colleagues in the Journal of the American Academy of Dermatology.


Click here to read the full article.


Apply now for one of the following 2026 dates:



October 24, November 14,

& December 12



  • ABIPP Part I

Four (4) hour virtual exam


  • ABIPP Path – Combined CCPM/ CSM Exam

For those with subspecialty in Pain Medicine

Two (2) hour virtual exam


  • ABIPP Competency Exam in IPM

For those without primary board certification

Two (2) hour virtual exam


  • ABIPP Competency Exam in Regenerative Medicine

Two (2) hour virtual exam


  • Controlled Substance Management Competency Exam

Two (2) hour virtual exam


  • Documentation, Coding, Compliance, Practice Management Competency Exam

Two (2) hour virtual exam

Exam Dates

Our Sponsor

Our Sponsor

Pain Medicine Case Reports (PMCR) and Editor-in-Chief Alaa Abd-Elsayed, MD, PhD would like to invite you to submit case reports and case series to the PMCR journal. Your article will be published free of charge.


Open access journals are freely available online for immediate worldwide open access to the full text of published articles. There is no subscription fee for open access journals. Open access journals are no different from traditional subscription-based journals: they undergo the same peer review and quality control as any other scholarly journal.


Interested in becoming a member of the PMCR Editorial Board?

Editorial board members are asked to review 2-6 manuscripts per year. Please submit your most up-to-date CV to sgold@asipp.org for consideration.


For more information or to submit your articles, click here.

We are excited to announce that Pain Medicine Case Reports (PMCR) journal (eISSN 2768-5152) has been accepted for inclusion in MEDLINE and PubMed, the prestigious bibliographic database of the U.S. National Library of Medicine. PMCR, a companion publication to the prestigious Pain Physician journal by ASIPP, joins its counterpart in achieving indexing in both MEDLINE and PubMed, marking ASIPP’s dual presence in these renowned databases.


The inclusion of PMCR journal in MEDLINE signifies a higher level of selectivity, as MEDLINE consists of the top 5,200 biomedical journals. This indexing also means that articles from PMCR will be searchable using NLM Medical Subject Headings (MeSH terms) and other metadata.


The selection for MEDLINE follows a rigorous evaluation process by reviewers from the Literature Selection Technical Review Committee (LSTRC). According to their criteria, the scientific quality of a journal’s content is the primary factor considered for indexing.


We extend our congratulations to the Pain Medicine Case Reports Editor-in-Chief, Deputy Editor-in-Chief, Journal Team, and Editorial Board for this achievement, which underscores the significance and excellence of this esteemed journal.

 

CASE REPORTS

Left Parasagittal Solitary Fibrous Tumor Presenting With Lumbar Radiculopathy-Like Symptoms: A Case Report


Thomas Hoang Ngo, DO, Andrew Garcia, MD, PharmD, and Peter Minh Huynh, MD

Peripheral Nerve Stimulation of the Saphenous Nerve at the Adductor Canal for Chronic Post-Surgical Knee Pain Following Total Knee Arthroplasty


Yacine Issioui, MD, Loc Lam, DO, and Emanuel Narcis Husu, MD

Therapeutic Effect of Suzetrigine in the Management of Notalgia Paresthetica: A Case Report


Brian Lee, MD, Wendy Wang, BA, Denny Cha, MD, and Jeffrey Lin, MD

 
 
 

BIBLIOMETRIC ANALYSIS

Bibliometric Analysis of Global Research on Radiofrequency in Chronic Pain Treatment


Fan Feng, Yongzhi Fan, Qianqian Xu, Xianbao Yao, and Yi Cai

RETROSPECTIVE STUDY

The Application of the Balloon Pre-Inflating Technique in Percutaneous Balloon Compression for Primary Trigeminal Neuralgia: A Retrospective Study


Wei Gao, Wu Di, Wei Zhang, Canying Li, Yaping Wang, Dingquan Zou, and Xinghua Jiang

OBSERVATIONAL STUDY

Absence of a Consistent Gut or Oral Microbial Signature in Fibromyalgia Under Strictly Controlled Clinical Conditions: A Multi-Compartment 16S rRNA Analysis


Gozde Celik, Ece Yanik, Nurten Inan, and Ayse Meltem Yalinay




ASIPP is in collaboration with Curi Medical Liability Program




Since this malpractice insurance program officially launched in November 2018, ASIPP has signed up hundreds of providers with an average savings of 30%. This is professional liability insurance tailored to our specialty and will stand up for us and defend our practices. 

 

Curi is a full-service advisory firm that serves physicians and their practices. Their valued advice is grounded in your priorities and elevated in your outcomes. They are driven by a deep understanding of your specific circumstances in medicine, business, and life. To read a few important points to keep in mind about the program, including discounts, administrative defense, cyber coverage, aggressive claims handling, and complimentary risk management CME activities, visit our website.



IMPORTANT UPDATE

SPRINT no longer classified as PNT 



SPR is happy to announce an important update regarding Humana Medicare Advantage. As of May 1, Humana is now recognizing SPRINT as a PNS therapy. Previously, SPRINT was categorized as PNT (Percutaneous Nerve Stimulation), which allowed denials on the grounds that the therapy fell outside the NCD.


Additional details are as follows:

Payer: Humana Medicare Advantage (click here to view policy)

Policy Title: Peripheral Nerve Stimulators

Policy changes: SPRINT no longer misclassified as PNT and is now appropriately classified as PNS. Humana is applying the Noridian Medicare LCD criteria to ALL PNS devices – Including SPRINT PNS!

Effective Date: 5/1/2025


Click here to view a PDF of the official policy update.

 

Group Purchasing Organization Offer Better Pricing and Creates Added Value


ASIPP has formed a partnership with Henry Schein and PedsPal, a national GPO that has a successful history of negotiating better prices on medical supplies and creating value-added services for independent physicians. Working with MedAssets, PedsPal provides excellent pricing on products like contrast media that alleviate some of the financial pressures you experience today.



Learn More


For updated information concerning tariffs on products, click here.

 
 

ASIPP, Fedora Healthcare Solutions Partnership


ASIPP offers our members the benefit of a unique revenue cycle management/ billing service.



We have received a tremendous amount of interest in the ASIPP billing and coding program.




Click here to learn more about the negotiated rate for practices and more!

Like and Follow ASIPP on Facebook, X, LinkedIn,

and YouTube for the most up-to-date news

related to you, your practice, and your patients!